Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07891533) titled 'Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera' on Oct. 17.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: AN2 Therapeutics, Inc
Condition:
Polycythemia Vera (SNOMED CT: 109992005)
Intervention:
Drug: Epetraborole
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2026
Target Sample Size: 75
Countries of Recruitment:
Australia
To know more, visit https://clinicaltrials.gov/study/NCT07891533
Disclaim...